Source-grounded facts extracted from ABBOTT LABORATORIES's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ABBOTT LABORATORIES: Board size increased from twelve to thirteen directors (effective 2026-04-24).
“On April 24, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective April 24, 2026.”
ABBOTT LABORATORIES updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026.”
ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.
“On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes”
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
“The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.”
ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
“On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes”
ABBOTT LABORATORIES: Board reduced from thirteen to twelve members, effective April 24, 2026 (effective 2026-04-24).
“On February 20, 2026, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s By-Laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective April 24, 2026.”
ABBOTT LABORATORIES: Increased board size from twelve to thirteen directors by amending Article III, Section 2 of the by-laws (effective 2025-12-12).
“On December 12, 2025, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons, effective as of December 12, 2025.”
Hubert L. Allen departed as Executive Vice President, General Counsel and Secretary at ABBOTT LABORATORIES.
“On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.”
Robert E. Funck, Jr. departed as Executive Vice President, Finance at ABBOTT LABORATORIES.
“Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.”
ABBOTT LABORATORIES reported the first quarter ended March 31, 2024 results: revenue $10.0 billion, EPS $0.70. Guidance raised.
“Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year – Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth 1 ABBOTT PARK, Ill., April 17, 2024 — Abbott today announced financial results for the first quarter ended March 31, 2024. • First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.”
ABBOTT LABORATORIES incurred revolving credit of up to $5 billion with JPMorgan Chase Bank, N.A. at SOFR rate, plus an applicable margin maturing fifth anniversary of the Effective Date.
“lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement provides Abbott with the ability to borrow up to $5 billion on an unsecured basis. Any borrowings under the Revolving Credit Agreement will mature and be payable on the fifth anniversary of the Effective Date. As of the date of this”
ABBOTT LABORATORIES terminated Five Year Credit Agreement, dated as of November 12, 2020 with JPMorgan Chase Bank, N.A. valued at Terminated all commitments; no outstanding borrowings (effective 2024-01-29).
“In connection with its entry into the Revolving Credit Agreement, on the Effective Date Abbott terminated all commitments outstanding under the Five Year Credit Agreement, dated as of November 12, 2020 (as amended by that certain Amendment No. 1, dated as of May 12, 2023, the “ Existing Credit Agreement ”), among Abbott, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
ABBOTT LABORATORIES entered into Five Year Credit Agreement with JPMorgan Chase Bank, N.A. valued at $5 billion unsecured borrowing capacity (effective 2024-01-29).
“On January 29, 2024 (the “ Effective Date ”), Abbott Laboratories, an Illinois corporation (“ Abbott ”), entered into a Five Year Credit Agreement (the “ Revolving Credit Agreement ”) with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
ABBOTT LABORATORIES reported full-year 2024 results: EPS full-year adjusted diluted EPS of $4.50 to $4.70. Guidance initiated.
“Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.”
ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2023 results: EPS Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19. Guidance initiated.
“On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023.”
ABBOTT LABORATORIES updated its third quarter ended Sept. 30, 2023 guidance (raised).
“Abbott today announced financial results for the third quarter ended Sept. 30, 2023. • Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. • Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and projects adjusted diluted EPS of $4.42 to $4.46, which represents an increase at the midpoint of the guidance range.”
ABBOTT LABORATORIES reported second quarter 2023 results: revenue $10.0 billion, EPS $0.78.
“in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –”
ABBOTT LABORATORIES shareholders rejected Shareholder proposal that Abbott’s Board of Directors adopt a policy that no financial performance metric shall be adjusted to exclude legal or compliance costs when evaluating performance for the purpose of senior executive compensation at the 2023-04-28 meeting.
“The shareholders rejected a shareholder proposal that Abbott’s Board of Directors adopt a policy that no financial performance metric shall be adjusted to exclude legal or compliance costs when evaluating performance for the purpose of senior executive compensation, with 14.44 percent of the votes cast voting "For" the proposal.”
ABBOTT LABORATORIES shareholders rejected Shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually, disclosing Abbott’s lobbying policies, procedures, and expenditures at the 2023-04-28 meeting.
“The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually, disclosing Abbott’s lobbying policies, procedures, and expenditures, with 22.97 percent of the votes cast voting "For" the proposal.”
ABBOTT LABORATORIES shareholders rejected Shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director at the 2023-04-28 meeting.
“The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 30.46 percent of the votes cast voting "For" the proposal.”
ABBOTT LABORATORIES shareholders rejected Shareholder proposal to lower the ownership threshold for calling special meetings of shareholders at the 2023-04-28 meeting.
“The shareholders rejected a shareholder proposal to lower the ownership threshold for calling special meetings of shareholders, with 4.26 percent of the votes cast voting "For" the proposal.”
ABBOTT LABORATORIES shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-04-28 meeting.
“The shareholders voted to approve Abbott’s Board of Directors’ recommendation that Abbott present shareholders with the opportunity to vote on the compensation awarded to its named executive officers annually, with 97.86 percent of the votes cast voting "1 Year" for the proposal.”
ABBOTT LABORATORIES shareholders approved Advisory vote to approve the compensation of Abbott’s named executive officers at the 2023-04-28 meeting.
“The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 90.01 percent of the votes cast voting "For" the proposal.”
ABBOTT LABORATORIES shareholders approved Ratification of Ernst & Young LLP as Abbott’s auditors at the 2023-04-28 meeting.
“The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors.”
ABBOTT LABORATORIES shareholders approved Election of Directors at the 2023-04-28 meeting.
“The shareholders elected Abbott’s entire Board of Directors.”
ABBOTT LABORATORIES reported first quarter ended March 31, 2023 results: revenue $9.7 billion, EPS First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03. Guidance reaffirmed.
“in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $9.7 billion driven by strong underlying base business performance – Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –”
ABBOTT LABORATORIES: Board of Directors size changed from 13 to 12 persons, effective April 28, 2023 (effective 2023-04-28).
“Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of twelve persons, effective April 28, 2023.”
ABBOTT LABORATORIES reported full year 2022 results: revenue $43.7 billion, EPS $3.91. Guidance initiated.
“--- News Release Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook – Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion – Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent – Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 – Continues to”
ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2022 results: revenue $10.1 billion, EPS $0.59.
“Abbott today announced financial results for the fourth quarter ended Dec. 31, 2022. • Fourth-quarter sales of $10.1 billion”
ABBOTT LABORATORIES: Amended and restated by-laws effective immediately, updating shareholder nomination and proposal procedures, special meeting mechanics, and other changes (effective 2022-12-09).
“On December 9, 2022, Abbott’s Board of Directors amended and restated Abbott’s by-laws (the “Amended and Restated By-Laws”), effective immediately. The Amended and Restated By-laws, among other things: · Update and clarify the procedural mechanics and information requirements for shareholder nominations of directors and shareholder proposals (other than proposals to be included in Abbott’s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at shareholder meetings, including to address matters relating to Rule 14a-19 under the Exchange Act; · Update certain procedural mechanics for special meetings of shareholders; · Clarify the powers of the Board and the Chair of a shareholder meeting to regulate conduct at such meeting; and · Make various other updates, including ministerial and conforming changes, as well as changes in furtherance of gender neutrality.”
Claire Babineaux-Fontenot was named as Director at ABBOTT LABORATORIES.
“On September 15, 2022, Claire Babineaux-Fontenot was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
Roxanne S. Austin departed as Director at ABBOTT LABORATORIES.
“On December 9, 2021, Roxanne S. Austin informed the Abbott Laboratories Board of Directors of her decision not to stand for re-election at the end of her current term expiring at the 2022 annual shareholders meeting in April.”
Robert B. Ford was appointed as Chairman of the Board at ABBOTT LABORATORIES.
“On December 10, 2021, Abbott’s Board of Directors appointed Robert B. Ford, Abbott’s President and Chief Executive Officer and a director, to the additional position of Chairman of the Board, effective upon Mr. White’s resignation.”
Miles D. White departed as Executive Chairman at ABBOTT LABORATORIES.
“Miles D. White informed the Abbott Laboratories (“Abbott”) Board of Directors that he will step down as Executive Chairman of the Board and as a director, effective December 10, 2021.”
Patricia P. Gonzalez was named as Director at ABBOTT LABORATORIES.
“On August 30, 2021, Patricia P. Gonzalez was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.